457 related articles for article (PubMed ID: 33826754)
1. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).
Broman KK; Hughes T; Dossett L; Sun J; Kirichenko D; Carr MJ; Sharma A; Bartlett EK; Nijhuis AAG; Thompson JF; Hieken TJ; Kottschade L; Downs J; Gyorki DE; Stahlie E; van Akkooi A; Ollila DW; Frank J; Song Y; Karakousis G; Moncrieff M; Nobes J; Vetto J; Han D; Farma JM; Deneve JL; Fleming MD; Perez MC; Lowe MC; Olofsson Bagge R; Mattsson J; Lee AY; Berman RS; Chai H; Kroon HM; Teras J; Teras RM; Farrow NE; Beasley G; Hui JYC; Been L; Kruijff S; Kim Y; Naqvi SMH; Sarnaik AA; Sondak VK; Zager JS
Cancer; 2021 Jul; 127(13):2251-2261. PubMed ID: 33826754
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis.
Broman KK; Hughes TM; Dossett LA; Sun J; Carr MJ; Kirichenko DA; Sharma A; Bartlett EK; Nijhuis AA; Thompson JF; Hieken TJ; Kottschade L; Downs J; Gyorki DE; Stahlie E; van Akkooi A; Ollila DW; Frank J; Song Y; Karakousis G; Moncrieff M; Nobes J; Vetto J; Han D; Farma J; Deneve JL; Fleming MD; Perez M; Baecher K; Lowe M; Bagge RO; Mattsson J; Lee AY; Berman RS; Chai H; Kroon HM; Teras RM; Teras J; Farrow NE; Beasley GM; Hui JY; Been L; Kruijff S; Boulware D; Sarnaik AA; Sondak VK; Zager JS;
J Am Coll Surg; 2021 Apr; 232(4):424-431. PubMed ID: 33316427
[TBL] [Abstract][Full Text] [Related]
3. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.
Eroglu Z; Broman KK; Thompson JF; Nijhuis A; Hieken TJ; Kottschade L; Farma JM; Hotz M; Deneve J; Fleming M; Bartlett EK; Sharma A; Dossett L; Hughes T; Gyorki DE; Downs J; Karakousis G; Song Y; Lee A; Berman RS; van Akkooi A; Stahlie E; Han D; Vetto J; Beasley G; Farrow NE; Hui JYC; Moncrieff M; Nobes J; Baecher K; Perez M; Lowe M; Ollila DW; Collichio FA; Bagge RO; Mattsson J; Kroon HM; Chai H; Teras J; Sun J; Carr MJ; Tandon A; Babacan NA; Kim Y; Naqvi M; Zager J; Khushalani NI
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002183
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Adoption and Outcomes of Nodal Observation for Patients with Melanoma and Sentinel Lymph Node Metastases.
Parvez E; Khosrow-Khavar F; Dumitra T; Nessim C; Bernard-Bédard É; Rivard J; Pravong V; Wang S; Gervais MK; Meterissian S; Dumitra S
Ann Surg Oncol; 2023 Feb; 30(2):1195-1205. PubMed ID: 36282456
[TBL] [Abstract][Full Text] [Related]
5. Real-World Adherence to Nodal Surveillance for Sentinel Lymph Node-Positive Melanoma.
Montgomery KB; Correya TA; Broman KK
Ann Surg Oncol; 2022 Sep; 29(9):5961-5968. PubMed ID: 35608800
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection.
Broman KK; Bettampadi D; Pérez-Morales J; Sun J; Kirichenko D; Carr MJ; Eroglu Z; Tarhini AA; Khushalani N; Schabath MB; Sarnaik A; Sondak VK; Zager JS
Ann Surg Oncol; 2021 Nov; 28(12):6978-6985. PubMed ID: 34363118
[TBL] [Abstract][Full Text] [Related]
7. Current management of patients with cutaneous melanoma with a positive sentinel lymph node.
Quildrian SD; Nardi WS; Scasso V; Novas C; Bella Quero L; Silva C
Medicina (B Aires); 2023; 83(3):376-383. PubMed ID: 37379534
[TBL] [Abstract][Full Text] [Related]
8. International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers.
Broman KK; Hughes TM; Bredbeck BC; Sun J; Kirichenko D; Carr MJ; Sharma A; Bartlett EK; Nijhuis AAG; Thompson JF; Hieken TJ; Kottschade L; Downs J; Gyorki DE; Stahlie E; van Akkooi A; Ollila DW; O'shea K; Song Y; Karakousis G; Moncrieff M; Nobes J; Vetto J; Han D; Hotz M; Farma JM; Deneve JL; Fleming MD; Perez M; Baecher K; Lowe M; Bagge RO; Mattsson J; Lee AY; Berman RS; Chai H; Kroon HM; Teras J; Teras RM; Farrow NE; Beasley GM; Hui JYC; Been L; Kruijff S; Sinco B; Sarnaik AA; Sondak VK; Zager JS; Dossett LA;
Ann Surg; 2023 May; 277(5):e1106-e1115. PubMed ID: 35129464
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy.
Farrow NE; Raman V; Williams TP; Nguyen KY; Tyler DS; Beasley GM
Ann Surg Oncol; 2020 Dec; 27(13):5121-5125. PubMed ID: 32314157
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Outcomes Between Surveillance Ultrasound and Completion Lymph Node Dissection in Children and Adolescents With Sentinel Lymph Node-Positive Cutaneous Melanoma.
Scoville SD; Stanek JR; Rinehardt H; Sutthatarn P; Abdelhafeez AH; Talbot LJ; Malek M; Leraas HJ; Tracy ET; Chen SY; Kim ES; Lotakis DM; Ehrlich PF; Favela JG; Le HD; Davidson J; Wilson CA; Seemann NM; Osman Y; Piche N; Hoang V; Petroze RT; Polites SF; McKay KG; Correa H; Lovvorn HN; Lee YM; Balagani A; Dasgupta R; Aldrink JH
Ann Surg; 2024 Mar; 279(3):536-541. PubMed ID: 37487006
[TBL] [Abstract][Full Text] [Related]
11. Recurrence factors in patients with cutaneous melanoma and positive sentinel lymph node treated in a single reference unit in Buenos Aires.
Nardi WS; Toffolo Pasquini M; Tomé F; Vigovich F; Cora MF; Quildrian SD
Medicina (B Aires); 2024; 84(2):279-288. PubMed ID: 38683513
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.
; Crystal JS; Thompson JF; Hyngstrom J; Caracò C; Zager JS; Jahkola T; Bowles TL; Pennacchioli E; Beitsch PD; Hoekstra HJ; Moncrieff M; Ingvar C; van Akkooi A; Sabel MS; Levine EA; Agnese D; Henderson M; Dummer R; Neves RI; Rossi CR; Kane JM; Trocha S; Wright F; Byrd DR; Matter M; Hsueh EC; MacKenzie-Ross A; Kelley M; Terheyden P; Huston TL; Wayne JD; Neuman H; Smithers BM; Ariyan CE; Desai D; Gershenwald JE; Schneebaum S; Gesierich A; Jacobs LK; Lewis JM; McMasters KM; O'Donoghue C; van der Westhuizen A; Sardi A; Barth R; Barone R; McKinnon JG; Slingluff CL; Farma JM; Schultz E; Scheri RP; Vidal-Sicart S; Molina M; Testori AAE; Foshag LJ; Van Kreuningen L; Wang HJ; Sim MS; Scolyer RA; Elashoff DE; Cochran AJ; Faries MB
JAMA Surg; 2022 Sep; 157(9):835-842. PubMed ID: 35921122
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Residual Nodal Disease at Completion Dissection Following Positive Sentinel Lymph Node Biopsy for Melanoma.
Sinnamon AJ; Song Y; Sharon CE; Yang YX; Elder DE; Zhang PJ; Xu X; Roses RE; Kelz RR; Fraker DL; Karakousis GC
Ann Surg Oncol; 2018 Nov; 25(12):3469-3475. PubMed ID: 30043316
[TBL] [Abstract][Full Text] [Related]
14. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.
Leiter U; Stadler R; Mauch C; Hohenberger W; Brockmeyer NH; Berking C; Sunderkötter C; Kaatz M; Schatton K; Lehmann P; Vogt T; Ulrich J; Herbst R; Gehring W; Simon JC; Keim U; Verver D; Martus P; Garbe C;
J Clin Oncol; 2019 Nov; 37(32):3000-3008. PubMed ID: 31557067
[TBL] [Abstract][Full Text] [Related]
15. Observation after a positive sentinel lymph node biopsy in patients with melanoma.
Bamboat ZM; Konstantinidis IT; Kuk D; Ariyan CE; Brady MS; Coit DG
Ann Surg Oncol; 2014 Sep; 21(9):3117-23. PubMed ID: 24833100
[TBL] [Abstract][Full Text] [Related]
16. Completion lymph node dissection in patients with sentinel lymph node positive cutaneous head and neck melanoma.
Huang K; Misra S; Lemini R; Chen Y; Speicher LL; Dawson NL; Tolaymat LM; Bagaria SP; Gabriel EM
J Surg Oncol; 2020 Nov; 122(6):1057-1065. PubMed ID: 32654173
[TBL] [Abstract][Full Text] [Related]
17. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era.
Mitra D; Ologun G; Keung EZ; Goepfert RP; Amaria RN; Ross MI; Gershenwald JE; Lucci A; Fisher SB; Davies MA; Lee JE; Bishop AJ; Farooqi AS; Wargo J; Guadagnolo BA
Ann Surg Oncol; 2021 Jul; 28(7):3480-3489. PubMed ID: 33856603
[TBL] [Abstract][Full Text] [Related]
18. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
[TBL] [Abstract][Full Text] [Related]
19. National Practice Patterns in the Management of the Regional Lymph Node Basin After Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma.
Sharon CE; Straker RJ; Li EH; Karakousis GC; Miura JT
Ann Surg Oncol; 2022 Dec; 29(13):8456-8464. PubMed ID: 36006494
[TBL] [Abstract][Full Text] [Related]
20. Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.
Kyrgidis A; Tzellos T; Mocellin S; Apalla Z; Lallas A; Pilati P; Stratigos A
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010307. PubMed ID: 25978975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
